Jaguar Health, Inc. (NASDAQ:JAGX) declared that the Company has entered a binding agreement of terms (the “Term Sheet”) for $6.0 million for the sale of partial rights to a possible tropical disease priority review voucher (“TDPRV”). Per the terms of the Term Sheet, Streeterville Capital, LLC (the “Investor”), has a right to 18% of the sale of a TDPRV that Jaguar’s wholly owned subsidiary, Napo Pharmaceuticals, Inc. (Napo) plans to pursue as incentive for the development of Napo’s lechlemer drug product candidate for the indication of the symptomatic relief of diarrhea in cholera patients.
Priority review vouchers are transferable and, in past transactions by other companies, have sold for prices ranging from $67 million to $350 million.
“We at Jaguar and Napo find it very rewarding to work in the pharmaceutical industry and be in a position to possibly help address such an important global health need and meet stakeholder expectations,” stated Lisa Conte, Jaguar’s founder, president, and CEO, “and we are thankful to the FDA for creating the priority review voucher program in an effort to drive development of drugs to benefit patients suffering from serious but often neglected diseases.”
“We believe the funds generated by the proposed transaction described in the Term Sheet will fully fund clinical development of lechlemer for the cholera-related indication. Moving this second-generation anti-secretory agent into clinical development gives the Company ‘another shot on goal’ – and we believe that lechlemer, which has the same mechanism of action as crofelemer and is significantly less costly to produce, may support development efforts to receive a TDPRV and provide long-term pipeline management of the novel anti-secretory mechanism of action of both crofelemer and lechlemer. Proof of concept trial design was achieved with a study in cholera patients with crofelemer at the renowned International Centre for Diarrhoeal Disease Research (icddr,b) in Bangladesh.”
Per the terms of the Term Sheet, the Note shall bear interest at prime per annum, and interest shall be prepaid each 12 months at the beginning of the period. The Note shall be due 48 months after its issue date. While the Note is outstanding, the Investor shall be entitled to 18% of the gross proceeds from the sale of the TDPRV (the “Return Bonus”). Jaguar has the right to buy out the Investor’s 18% right by redeeming the Note at a 12.5% premium after six months of entering into a final agreement, and before the release of data from a pivotal lechlemer trial for the cholera-related indication. Once the Note is paid in full, the Return Bonus will decrease to 1.0% in perpetuity.
In the event that, prior to redeeming the Note, the Company abandons the clinical trial with lechlemer for an indication of the symptomatic relief of diarrhea in cholera patients (such abandonment, which is deemed to include (i) failure to start the Phase 1 clinical trial by July 1, 2022 or (ii) failure to meet all primary endpoints in the pivotal trial with statistical significance, “Trial Default”), then, at Investor’s sole election, the Company will immediately pay to Investor an amount equal to 125% multiplied by all outstanding principal and accrued and unpaid interest on the Note as of the date of the Trial Default. The final terms of the Note issuance are subject to the negotiation and finalization of the definitive agreement relating to the Note issuance.
Priority review vouchers are granted by the U.S. Food and Drug Administration (FDA) as an incentive to develop treatments for neglected diseases and rare diseases. The voucher entitles the bearer to regulatory review by the FDA in approximately six months rather than the standard ten months. The FDA awards a priority review voucher following approval of a treatment for a neglected disease, rare pediatric disease, or medical countermeasure.
Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae. According to the Centers for Disease Control and Prevention of the U.S. Department of Health & Human Services, an estimated 3‑5 million cholera cases and more than 100,000 cholera-related deaths occur each year around the world. The infection is often mild or without symptoms but can sometimes be severe. Approximately one in 10 of infected persons will have severe disease characterized by profuse watery diarrhea, vomiting, and leg cramps. In these people, rapid loss of body fluids leads to dehydration and shock. Without treatment, death can occur within hours. The largest cholera outbreak in recorded history recently occurred in Yemen. According to Oxfam, the number of cholera cases in Yemen in 2019 was the second largest ever recorded in a country in a single year, surpassed only by the numbers in Yemen in 2017. According to the Brookings Institution, cholera continues to spread in Yemen, with 180,000 new cases reported in the first eight months of 2020.
As recently announced, Napo is receiving preclinical services support from the National Institute of Allergy and Infectious Diseases (NIAID) for a 28-day preclinical toxicology and safety study in dogs that was initiated January 6, 2021 for lechlemer for the proposed cholera-related indication. NIAID is part of the National Institutes of Health. Under NIAID’s suite of preclinical services, NIAID-funded contractors are conducting the dog study. As previously announced, a 28-day preclinical toxicology study in rats to support lechlemer development for the symptomatic relief of diarrhea from cholera was initiated in July of last year. Under NIAID’s suite of preclinical services, NIAID-funded contractors also conducted the initial 7-day dog and rat toxicology studies, and completion of these shorter studies allowed for initiation of the longer-term, 28-day, IND-enabling toxicity studies.
Lechlemer is a drug candidate under the botanical guidance of the FDA. It is a standardized and proprietary Napo botanical extract that is distinct from crofelemer, the active pharmaceutical agent in Mytesi®, the Company’s FDA-approved drug product. Lechlemer is sustainably derived from the same source as Mytesi: the Croton lechleri tree.
Jaguar Health, Inc., belongs to Healthcare sector and Biotechnology industry. The company’s Market capitalization is $264.50MB with the total Outstanding Shares of 107.34M. On 1-14-2021 (Thursday), JAGX‘s stock construct a change of -0.59% in a total of its share price and finished its trading at 3.67.
JAGX Stocks 381.62% Far from 50 Day Moving Average
After a stumble in the market that brought JAGX to its low price for the period of the last 52 weeks, Jaguar Health, Inc. was unable to take a rebound, for now settling with 1882.76% of loss for the given period.
Having a look at past record, we’re going to look at various forwards or backwards shifting developments regarding JAGX. The firm’s shares rose 83.58% in the past five business days and grew 969.88% in the past thirty business days. In the previous quarter, the stock rose 1071.43% at some point. The output of the stock increased 458.16% within the six-month closing period, while general annual output gained 356.12%. The company’s performance is now positive at 352.76% from the beginning of the calendar year.
Earnings per Share Details of Jaguar Health, Inc.
Lets a quick look at JAGX’s past reported and future predictions of growth using the EPS Growth. EPS growth is a percentage change in standardized earnings per share over the trailing-twelve-month period to the current year-end.
The company posted a value of $94.10% as earning-per-share over the last full year, while a chance, will post $0 for the coming year. In-depth, if we analyze for the long-term EPS Growth, the out-come was 0 for the past five years and the scenario is totally different as the current prediction is 40.00% for the next five year.
P/S, P/E, P/C and P/B/ SMA50, SMA 200:
The price-to-sales is a valuation ratio that relates a company’s stock price to its revenues. The price-to-sales ratio is a symbol of the value placed on each dollar of a company’s sales or taxes. As of now, JAGX has a P/S, P/E and P/B values of 31.87, 0 and 73.80 respectively. P/E and P/B ratios both are used on a regular basis by the investor to measure the value of the company and to get the right amount of the share.
Its P/Cash valued at 203.46. The price-to-cash-flow ratio is a stock valuation indicator that measures the value of a stock’s price to its cash flow per share. Investors focus on the profitability proportions of the company that how the company performs at profitability side. Return on equity ratio or ROE is a significant indicator for prospective investors as they would like to see just how effectively a business is using their cash to produce net earnings.
Watching some historical volatility numbers on shares of Jaguar Health, Inc. (JAGX) we can see that the 30 days volatility is presently 33.53%. The 7 days volatility is 29.42%. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period.
The company has a beta of Jaguar Health, Inc. 1.00 indicates that its price is correlated with the market. Less than 1.00 shows less volatility than the market. Beta greater than 1.00 indicates that the security’s price is theoretically more volatile than the market.
As a return on equity, Jaguar Health, Inc. (NASDAQ: JAGX) produces -853.40%. Because it would be easy and highly flexible, ROI measurement is among the most popular investment ratios. Executives could use it to evaluate the levels of performance on acquisitions of capital equipment whereas investors can determine that how the stock investment is better. The ROI entry for JAGX’s scenario is at -208.00%. Another main metric of a profitability ratio is the return on assets ratio or ROA that analyses how effectively a business can handle its assets to generate earnings over duration of time. Jaguar Health, Inc. (JAGX) generated -98.40% ROA for the trading twelve-month.
What do you mean by simple moving average (SMA)?
Based on a recent bid, its distance from 20 days simple moving average is 143.71%, and it has a distance of 571.84% from the 200 days simple moving average.
The payout ratio shows the proportion of earnings paid out as dividends to shareholders, typically expressed as a percentage of the company’s earnings. The payout ratio can also be expressed as dividends paid out as a proportion of cash flow. The payout ratio is also known as the dividend payout ratio. The Company’s payout ratio was 0 and Price to free cash flow remained $0.